Lars Engstrom is a seasoned scientist with extensive experience in translational biology and oncology research. Currently serving as Senior Principal Scientist, Translational Biology at Iambic Therapeutics since July 2025, Engstrom previously contributed significantly at Mirati Therapeutics as a Senior Principal Scientist, leading the MTA-cooperative PRMT5 pharmacology team through key program milestones to IND submission. Prior roles include Senior Scientist in the Oncology Research unit at Pfizer, where Engstrom developed critical in vitro assays for crizotinib and identified a novel CNS-penetrant inhibitor, as well as Senior Associate Scientist in Drug Safety R&D, which supported FDA approval processes. Engstrom began a career in research at the University of Michigan as a Research Associate, focusing on DNA binding and protein interactions within the Myc/Max/Mad network. Educational qualifications include a Bachelor of Science from the University of Michigan.
This person is not in the org chart
This person is not in any teams
This person is not in any offices